Literature DB >> 24935471

ADAM10 regulates proliferation, invasion, and chemoresistance of bladder cancer cells.

Lin Fu1, Nan Liu, Yong Han, Chengyao Xie, Qingchang Li, Enhua Wang.   

Abstract

A disintegrin and metalloprotease 10 (ADAM10) is upregulated in several cancers and associates with malignant cancer progression. However, its expression pattern in bladder cancer remains unexplored. In the present study, we examined ADAM10 expression in 105 bladder cancer specimens using immunohistochemistry. We found ADAM10 overexpression in 51 of 105 (48.5 %) bladder cancer specimens. ADAM10 overexpression associated with advanced tumor stage (p = 0.001) and tumor grade (p = 0.018). To explore its biological functions in bladder cancer cells, small interfering RNA (siRNA) knockdown was performed in 5,637 and T24 cell lines. Cell Counting Kit-8 (CCK8) assay and Matrigel invasion assay showed that ADAM10 depletion decreased cell proliferation, migration, and invasion. In addition, ADAM10 knockdown increased the level of cisplatin-induced apoptosis. In conclusion, ADAM10 is overexpressed in bladder cancer and regulates malignant cell growth and invasion, which makes it a candidate therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935471     DOI: 10.1007/s13277-014-2201-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

1.  Hypermethylation in bladder cancer: biological pathways and translational applications.

Authors:  Marta Sánchez-Carbayo
Journal:  Tumour Biol       Date:  2012-01-25

2.  Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma.

Authors:  Shun-Yao Ko; Shu-Chun Lin; Yong-Kie Wong; Chung-Ji Liu; Kuo-Wei Chang; Tsung-Yun Liu
Journal:  Cancer Lett       Date:  2005-11-23       Impact factor: 8.679

Review 3.  Emerging roles of ADAM and ADAMTS metalloproteinases in cancer.

Authors:  N Rocks; G Paulissen; M El Hour; F Quesada; C Crahay; M Gueders; J M Foidart; A Noel; D Cataldo
Journal:  Biochimie       Date:  2007-09-02       Impact factor: 4.079

4.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

5.  Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.

Authors:  Uwe Lendeckel; Jana Kohl; Marco Arndt; Stacy Carl-McGrath; Hans Donat; Christoph Röcken
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-30       Impact factor: 4.553

6.  Berberine inhibits the migration and invasion of T24 bladder cancer cells via reducing the expression of heparanase.

Authors:  Lei Yan; Keqiang Yan; Wang Kun; Lin Xu; Qian Ma; Yueqing Tang; Wei Jiao; Gangli Gu; Yidon Fan; Zhonghua Xu
Journal:  Tumour Biol       Date:  2012-10-12

Review 7.  Role of ADAMs in cancer formation and progression.

Authors:  Michael J Duffy; Eadaoin McKiernan; Norma O'Donovan; Patricia M McGowan
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

8.  Expression and biological roles of SATB1 in human bladder cancer.

Authors:  Bin Han; Lan Luan; Zhenqun Xu; Bin Wu
Journal:  Tumour Biol       Date:  2013-05-22

9.  ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.

Authors:  Cheng-lin Yang; Feng-qin Jiang; Feng Xu; Gui-xing Jiang
Journal:  Tumour Biol       Date:  2012-05-13

10.  Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference.

Authors:  Qin Xu; Xiuming Liu; Wantao Chen; Zhiyuan Zhang
Journal:  J Transl Med       Date:  2010-12-20       Impact factor: 5.531

View more
  14 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

2.  Clinical significance of ADAM10 expression in laryngeal carcinoma.

Authors:  Bo You; Miao Gu; Xiaolei Cao; Xingyu Li; Si Shi; Ying Shan; Yiwen You
Journal:  Oncol Lett       Date:  2016-12-28       Impact factor: 2.967

Review 3.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

4.  The miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer.

Authors:  Yang Li; Hui Deng; Lei Lv; Cheng Zhang; Liting Qian; Jun Xiao; Weidong Zhao; Qi Liu; Daming Zhang; Yingwei Wang; Jun Yan; Hongyu Zhang; Yinghua He; Jingde Zhu
Journal:  Oncotarget       Date:  2015-04-30

5.  Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma.

Authors:  Bo You; Ying Shan; Si Shi; Xingyu Li; Yiwen You
Journal:  Cancer Sci       Date:  2015-10-14       Impact factor: 6.716

6.  PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.

Authors:  Zheng Bo Hu; Xiao Hong Liao; Zun Ying Xu; Xiao Yang; Chao Dong; An Min Jin; Hai Lu
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

7.  Overexpression of A disintegrin and metalloprotease 10 promotes tumor proliferation, migration and poor prognosis in hypopharyngeal squamous cell carcinoma.

Authors:  Chuanjin Ding; Qicheng Zhang; Yan Chen; Xiaobo Zhang; Pei Wu; Zhenxin Zhang
Journal:  Oncol Rep       Date:  2017-06-27       Impact factor: 3.906

8.  Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas.

Authors:  Kerstin Lang; Nadine Bonberg; Sibylle Robens; Thomas Behrens; Jan Hovanec; Thomas Deix; Katharina Braun; Florian Roghmann; Joachim Noldus; Volker Harth; Karl-Heinz Jöckel; Raimund Erbel; Yu Chun Tam; Andrea Tannapfel; Heiko Udo Käfferlein; Thomas Brüning
Journal:  Oncotarget       Date:  2017-09-08

9.  Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73.

Authors:  ZhengBo Hu; ZunYing Xu; XiaoHong Liao; Xiao Yang; Cao Dong; KuaDi Luk; AnMin Jin; Hai Lu
Journal:  Onco Targets Ther       Date:  2015-11-20       Impact factor: 4.147

10.  CMTM8 inhibits the carcinogenesis and progression of bladder cancer.

Authors:  Denghui Gao; Hao Hu; Ying Wang; Weidong Yu; Jianhua Zhou; Xiaofeng Wang; Weiping Wang; Chunyan Zhou; Kexin Xu
Journal:  Oncol Rep       Date:  2015-12       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.